Exact Mass: 305.953
Exact Mass Matches: 305.953
Found 159 metabolites which its exact mass value is equals to given mass value 305.953,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Myebrol
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D009676 - Noxae > D000477 - Alkylating Agents D000970 - Antineoplastic Agents Same as: D02020
2,3,4,5-Tetrachloro-4'-biphenylol
D004785 - Environmental Pollutants > D011078 - Polychlorinated Biphenyls
2,2,4,6-Tetrachloro-4-biphenylol
D004785 - Environmental Pollutants > D011078 - Polychlorinated Biphenyls
ascidiathiazone B
An organic heterotricyclic compound, that is 5,10-dioxo-5,10-dihydro-1H-[1,4]thiazino[3,2-g]quinoline 4,4-dioxide substituted at position 7 by a carboxy group. It is an anti-inflmmatory alkaloid obtained from Aplidium.
Broxuridine
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent D009676 - Noxae > D000963 - Antimetabolites D011838 - Radiation-Sensitizing Agents D000970 - Antineoplastic Agents relative retention time with respect to 9-anthracene Carboxylic Acid is 0.233 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.226 5-BrdU (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA. 5-BrdU is commonly used in the detection of proliferating cells.
Rimoprogin
C254 - Anti-Infective Agent > C514 - Antifungal Agent
tert-butyl N-(4-bromo-5-formyl-1,3-thiazol-2-yl)carbamate
3-(4-BROMOPHENYL)-5-(THIOPHEN-2-YL)-1,2,4-OXADIAZOLE
Sodium 5-oxo-1-(4-sulfophenyl)-4H-pyrazole-3-carboxylate
2-(2-chloro-6-fluorobenzyl)-4,5-dichloropyridazine-3-(2h)-one
tert-Butyl (2-bromo-6-chloropyridin-3-yl)carbamate
N-(5-bromo-2-methoxypyridin-3-yl)cyclopropanesulfonamide
ACETIC ACID ACETOXY-(4-CHLORO SULFONYL PHENYL)METHYL ESTER
Cyclohexadienyliumiron(0) tricarbonyl tetrafluoroborate
methyl 2-(trimethylstannyl)thiophene-3-carboxylate
TERT-BUTYL (5-BROMO-2-CHLOROPYRIDIN-3-YL)CARBAMATE
3-(3-Bromo-4-methoxyphenyl)benzoic acid, 2-Bromo-4-(3-carboxyphenyl)anisole, 3-Bromo-3-carboxy-4-methoxybiphenyl
5-[2-(METHYLTHIO)PYRIMIDIN-4-YL]THIOPHENE-2-SULFONYL CHLORIDE
(5-BROMO-2-HYDROXY-4-METHOXYPHENYL)(PHENYL)METHANONE
Mitolactol
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent D009676 - Noxae > D000477 - Alkylating Agents D000970 - Antineoplastic Agents
2-(3-Bromophenyl)-5-(thiophen-2-yl)-1,3,4-oxadiazole
2-[(2-bromophenyl)methoxy]benzoic Acid
ML-097 (CID-2160985) is a pan Ras-related GTPases activator that can activate Rac1, cell division cycle 42, Ras, and Rab7[1].
5-chloro-N-(1,3-dioxo-5-isoindolyl)-2-thiophenecarboxamide
mitobronitol
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D009676 - Noxae > D000477 - Alkylating Agents D000970 - Antineoplastic Agents
Technetium TC-99M medronate
V - Various > V09 - Diagnostic radiopharmaceuticals > V09B - Skeleton > V09BA - Technetium (99mtc) compounds D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
3-chloro-4-fluoro-N-(3-pyridinyl)-1-benzothiophene-2-carboxamide
D-ribulose 1,5-bisphosphate(4-)
Tetraanion of D-ribulose 1,5-bisphosphate arising from deprotonation of all four phosphate OH groups; major species at pH 7.3.
2,3,4,5-Tetrachloro-4-biphenylol
D004785 - Environmental Pollutants > D011078 - Polychlorinated Biphenyls
2′-Bromo-2′-deoxyuridine
2′-Bromo-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
